

# SAPH2026

THE 19<sup>TH</sup> ANNUAL CONFERENCE OF  
THE SAUDI ASSOCIATION FOR PULMONARY HYPERTENSION  
12-14 FEBRUARY 2026 | JEDDAH HILTON, SAUDI ARABIA

Organized By:



In Collaboration With:



## FINAL PROGRAM









Red Mermaid, this is what this modern city is called. It is the largest city in Makkah Province, the largest sea port on the Red Sea, and the second-largest city in Saudi Arabia after the capital city, Riyadh. With a population of about 4 million people (as of 2014), Jeddah is an important commercial hub in Saudi Arabia and that's why considered as the country's commercial capital. Jeddah is considered also a big Islamic tourist destination in Saudi Arabia and the principal gateway to Makkah, Islam's holiest city, which Muslims are required to visit at least once in their lifetime. It is also a gateway to Madina, the second holiest place in Islam. Jeddah is the most easygoing city in the kingdom and cosmopolitan part of the country with much diversity in its expat population. Historically, politically and culturally, Jeddah was a major city of Hejaz Vilayet, the Kingdom of Hejaz and other regional political entities according to Hijazi history books. It is the 100th largest city in the world by land area. Jeddah is located in the western region of Saudi Arabia (called Hejaz Tihamah) which is in the lower Hijaz Mountains and lies with Red Sea coast.

#### Red Sea

The Red Sea is one of the world's main navigation routes, connecting three continents: Africa, Asia, and Europe. The Red Sea known in Arabic (Al-Bahr Al-Ahmar) and historically, it was also known to western geographers as Mare Mecca (Sea of Mecca). Narrow strip of water extending southeastward from Egypt, for about 1,200 miles (1,930 km) to the Bab el-Mandeb Strait, which connects with the Gulf of Aden and thence with the Arabian Sea. Its maximum width is 190 miles, its greatest depth 9,974 feet (3,040 meters), and its area approximately 174,000 square miles. The Red Sea is a rich and diverse ecosystem, the 2,000 km long coral reef system in the Red Sea ranks among the top five coral reefs in the world. The Red Sea is known for its picturesque diving areas which considered also one of the best dives in Saudi Arabia. The importance of the Red Sea lies in its being a major transit point for the export of oil from the Arabian Gulf to the world markets.

#### Tourism in Jeddah

Jeddah is a modern city with a high potential to spend the most amazing times, whether for recreation or work. It is a city that beats with vibrant and pleasure when everyone enjoys a visit, both young and old through entertainment and cultural events throughout the year. In term of urban development, Jeddah has done much to improve its image over the years. North Jeddah

in particular has undergone massive redevelopment to make the Corniche (Beach) more attractive to visitors, while upscale department stores and malls have expanded shoppers' choices. The city has many popular hotels and resorts as well as famed for its international cuisine and seafood, and it remains a sweet spot for seasoned and novice scuba divers. The Al Balad district, the heart of old Jeddah, is a nostalgic testament to the city's by gone days, with the beautiful coral architecture of historic buildings casting some welcome shade over the bustling souqs where shopkeepers hawk their goods. There are some listed attractions; you might have the interest to visit: - Jeddah Regional Museum of Archaeology & Ethnography - Humane Heritage Museum - Nasseef House - Al Tayibat City Museum for International Civilization - Floated Mosque (Alrahmah Mosque) - Fakieh Aquarium - King's Fountain - Aljoharah Stadium

#### Transportation in Jeddah

Jeddah, relies on air and sea transportation (King Abdulaziz Airport & Islamic Jeddah port) which are the most important means of transporting passengers to and from the city. In addition to air and sea traffic, Jeddah is connected to Saudi Arabia's most important road, the Highway 40, which crosses the entire Arabian Desert to Dammam. Adventurous expats can board an overland bus to Abha, Dammam, Ji'zan, Najran, Riyadh, Taif, or Yanbu. On the end of 2017, the Saudi Government will start operate Al Haramain Express Train Project, one of the important elements in the expansion of the railway network in the kingdom. Which is specifically designed for Hajj Season due to the growing number of pilgrims from inside and outside the kingdom. It will be connected between Makkah and Madinah through Jeddah City with a length of more than 450 km equipped with modern signaling and communication system. Although the Saudi government has instigated a plan to develop a public transport system in Jeddah, which includes a metro, busses and ferries, it will take at least seven years to be up and running. Until this point, the Short-term visitors rely on taxis to get around (white limousines recognizable by the taxi sign on top of the car), rental car, or via a shuttle service to most international hotels in town.



#### Badges:

Name badges must be visible and used at all times, anywhere at the conference venue, and off- site social activities.

#### Badges Color Coding:

<b>FACULTY</b>
<b>DELEGATE</b>
<b>EXHIBITOR</b>
<b>STAFF</b>

#### CME Certification:

This Conference is accredited by The Saudi Commission for Health Specialties (SCFHS) for 12 CMEs. In order to receive the CMEs, it is required to fill in the Evaluation and CME Acquisition Form which will be available at the Registration Desk throughout the conference.

Though Certificate of Attendance hard copies are not accepted by the SCFHS, but if you like to have one, kindly request through our website.

#### Conference Packets:

Conference Packets will be distributed to registered participants at the Registration Desk.

#### Faculty Check in:

There is a dedicated faculty lounge & preview room for faculty's registration and badge collection and is operational at the same time as the registration desks.

#### Food & Beverage:

Coffee breaks and lunch will be open to registered delegates. The hotel also offers a variety of all day dining restaurants to choose from.

#### Automated Teller Machines (ATM):

There is an ATM located in the Hotel Lobby

#### Rules:

Smoking Policy in the Hotel: The entire hotel is non smoking. Mobile Phones- Delegates are kindly requested to keep their mobile phones in the off mode in meeting rooms when scientific sessions are in progress.

#### Parking:

24 hours valet parking is available at the Conference venue.


#### Prayer Room:

Prayer rooms are available in the Event Centre.

#### Evacuation Assembly Point:

In case of an emergency evacuation procedure please proceed in an orderly fashion to the open area in front of the Events Centre. Please follow the instructions of the Hotel Staff Wardens at all times.





## About Us

The Saudi Association for Pulmonary Hypertension (SAPH) is a medical and research national group of many medical specialists, who shared a common interest in the field of Pulmonary Vascular Diseases (PVD). The main goal for SAPH is to increase the awareness and the knowledge of pulmonary vascular diseases in the society and between the medical professionals, and to start variety of research projects in the field of pulmonary vascular diseases in the region, in order to improve the understanding, and quantify the size of the problem in this part of the world. SAPH is registered and operates under the Saudi Thoracic Society.

## Objectives

- To investigate the incidence, prevalence, and pathobiology of PVD in underserved areas that, to date, have not been well characterized
- To identify unique characteristics of the illness including its morbidity and mortality
- To establish effective therapies, which will be accessible to the affected patients
- To develop national guidelines for diagnosis & management of PVD
- To provide expertise to areas with healthcare disparities that will address issues related to the education and training of healthcare professionals in the area of PVD
- To focus on improving the treatment of PVD, by promoting basic and clinical research, by educating physicians, and by assisting the development and conduct of clinical trials following the highest standards of clinical research
- To provide consultative services to health agencies and industry regarding advancing the treatment of PVD.
- To promote public awareness through different means including print and electronic media and public seminars

## Activities

- SAPH has established a national database on patients with PVD to allow a meaningful understanding of the similarities and differences in the spectrum of the illness between different regions in the kingdom and other countries in the world
- SAPH has developed a web-based, multilingual educational materials and guidelines on the management of pulmonary vascular disease accessible to people involved in healthcare delivery
- SAPH has been conducting conferences and workshops on the modern methods to evaluate patients, determine accurate diagnoses, and monitor the efficacy of treatments.
- SAPH International Outreach Program (SIOP) was founded to establish line of communication and collaboration with our colleagues and friends from different international societies, organizations, or institutions who are providing Pulmonary Hypertension Services. International Outreach Program will entail, but not limited to, conducting conferences, symposia, workshops, masterclasses, demonstrations, joint research activities, and visiting professor/ expertise exchange programs.



# INTERNATIONAL OUTREACH PROGRAM

## PURPOSE:

SAPH International Outreach Program (SIOP) was founded to establish line of communication and collaboration with our colleagues and friends from different international societies, organizations, or institutions who are providing Pulmonary Hypertension Services. International Outreach Program will entail, but not limited to, conducting



Conferences



Symposia



Workshops



Referrals



Masterclasses



Telemedicine



Consultations



Visiting Professor



Onsite  
Demonstrations



Joint Research  
Activities



Expertise  
Exchange Program



Dear Colleagues,

It gives me great pleasure to welcome you all to the 19<sup>th</sup> Annual Conference of the Saudi Association for Pulmonary Hypertension (**SAPH2026**) which will be held at Hilton Hotel, Jeddah, Saudi Arabia on **12-14 February 2026**.

SAPH is maintaining the quest for development and progress year after year. **SAPH2026** aims to create a platform for regional medical professionals to engage in exchange for knowledge and expertise on the latest and best practice methods in Pulmonary Hypertension.

As a Continuation of Successful Collaboration between the Saudi Association for Pulmonary Hypertension (**SAPH**) and the Pulmonary Vascular Research Institute (PVRI), it has been proven that it is highly successful and helped in introducing physicians in The Middle East and North African countries to the world experts in the field of Pulmonary Hypertension and to the most advanced developments in understanding and managing Pulmonary Hypertension.

The Scientific Committee is planning a comprehensive Scientific Program covering all aspects of Pulmonary Vascular Diseases in both Adult & Children, from the basics of Pathobiology and Pathophysiology, Diagnosis, Classification and Management to the most advanced development in Therapies and Interventional Modalities.

The program will be covered by the internationally recognized leaders in the field of Pulmonary Hypertension.


We are much appreciative to all our distinguished speakers and chairpersons. My hope is that all those who are practicing physicians will make an effort to attend and benefit from this Conference.

With my best regards,



**Prof. Abdullah M. Aldalaan, MD**

Chairman, the 19<sup>th</sup> Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)  
Chairman, Saudi Association for Pulmonary Hypertension (SAPH)  
Consultant, Pulmonary Medicine  
Director, Pulmonary Hypertension Program, Lung Health Center  
King Faisal Specialist Hospital & Research Centre  
Professor of Medicine, Alfaisal University  
*Riyadh, Saudi Arabia*



**Prof. Abdullah M. Aldalaan, MD**

Chairman, the 19<sup>th</sup> Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)  
Chairman, Saudi Association for Pulmonary Hypertension (SAPH)  
Consultant, Pulmonary Medicine  
Director, Pulmonary Hypertension Program, Lung Health Center  
King Faisal Specialist Hospital & Research Centre  
Professor of Medicine, Alfaisal University  
*Riyadh, Saudi Arabia*



**Abdullah M. Alkhodair, MD, FRCPC**

Chairman, Scientific Committee  
Consultant, Interventional Cardiology/  
Pulmonary Hypertension  
Adult Cardiology Program Director  
King Fahad Medical City  
*Riyadh, Saudi Arabia*



**Fayez K. Alahmadi, MD**

Consultant, Pulmonary Medicine,  
Pulmonary Hypertension and Balloon  
Pulmonary Angioplasty,  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*



**Shaya Ahmed Alshaya, MD**

Consultant Adult Pulmonary, Pulmonary  
Hypertension  
Head, Adult Pulmonary Department at King  
Fahad Medical City  
Head, Pulmonary Hypertension Clinical Program  
& Service at King Fahad Medical City  
Program Director, Internal Medicine Residency  
Program, Riyadh Second Health Cluster  
*Riyadh, Saudi Arabia*



**Bader J. Alghamdi, MD**

Consultant, Pulmonary Medicine, Pulmonary  
Hypertension, & Clinical Cardiopulmonary  
Exercise Testing  
Assistant Professor in King Saud bin Abdulaziz  
Uni. for Health Sciences (KSAU-HS)  
Section Head of Respiriology and Director of  
Respirology Fellowship Training Program,  
Ministry of National Guard  
*Jeddah, Saudi Arabia*



**Khaled M. Alobaidellah, MD, FRCPC**

Consultant Adult Pulmonary, Pulmonary  
Hypertension,  
Pulmonary Medicine division,  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**Ragdah Hussain Arif, MD, FRCPC, ABIM**

Consultant, Pulmonologist and Pulmonary  
Hypertension  
Assistant Professor, King Abdulaziz  
University/Hospital  
*Jeddah, Saudi Arabia*



**Ahmed Krimly, MD**

Consultant, Adult Congenital  
Heart Disease and Interventional Cardiology,  
King Faisal Cardiac Centre,  
King Abdul Aziz Medical City  
*Jeddah, Saudi Arabia*



**Badr Alzahrani, MD, FACC**

Consultant Interventional Cardiology  
American Board of Internal Medicine,  
Cardiology and Interventional Cardiology,  
Prince Sultan Cardiac Center  
*Riyadh, Saudi Arabia*



**Nawal Al Gubaisi, MD, SSC-Med, SF-PD**

Consultant Pulmonologist  
Pulmonary Hypertension Specialist  
Head of Pulmonary Medicine Unit  
King Fahad Medical Military Complex  
*Dhahran, Saudi Arabia*



**Manal Alhazmi, MBBS, MSHA**

Consultant Pulmonary & Critical Care  
Ad Diriyah Hospital, 3rd Health Cluster  
*Riyadh, Saudi Arabia*





**Faisal Aloufi, MD**  
Consultant, Cardiothoracic Radiologist  
Cardiothoracic Imaging Fellowship in  
University of Toronto, Canada  
*Riyadh, Saudi Arabia*



**Noura Alturaif, MD**  
Consultant, Pulmonary and  
Pulmonary Hypertension  
Lung Health Department  
King Faisal Specialist Hospital and  
Research Centre  
*Riyadh, Saudi Arabia*



**Prof. Majdy Idrees, MD, FRCPC, FPVRI**  
Head, Pulmonary Vascular Unit  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**Hussam Sakkijha, MD**  
Consultant, Pulmonary,  
Critical Care and Sleep Medicine  
King Fahad Medical City,  
*Riyadh, Saudi Arabia*



**Khalid Al Najashi, MD, MBBS**  
Consultant, Interventional ACHD and  
Pediatric Cardiology  
Prince Sultan Cardiac Center  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**Abdallah M. Alasiri, MD**  
Consultant Pulmonology & Internal Medicine,  
Head of Respiratory and TB unit,  
Director of GIM Training Program,  
Aseer Central Hospital  
*Abha, Saudi Arabia*



**Omar Al Tamimi, MD**  
Consultant, Pediatric Cardiology  
King Salman Heart Center  
King Fahad Medical City  
*Riyadh, Saudi Arabia*




**Mai Alzaydi, PhD**  
Researcher in Mitochondrial and Vascular Biology  
General Manager, Bioengineering Institute  
King Abdulaziz City for Science and Technology  
(KACST)  
*Riyadh, Saudi Arabia*



**Hassan S. Alorainy, BsRC, RRT, FAARC**  
Executive Director,  
Saudi Association for Pulmonary Hypertension (SAPH)  
Senior Clinical Respiratory Specialist  
*Riyadh, Saudi Arabia*







**Prof. Abdullah M. Aldalaan, MD**  
Chairman, the 19<sup>th</sup> Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)  
Chairman, Saudi Association for Pulmonary Hypertension (SAPH)  
Consultant, Pulmonary Medicine  
Director, Pulmonary Hypertension Program, Lung Health Center  
King Faisal Specialist Hospital & Research Centre  
Professor of Medicine, Alfaisal University  
*Riyadh, Saudi Arabia*



**Prof. Luke Howard, MD, DPhil, FRCP**  
Consultant Pulmonologist,  
Hammersmith Hospital,  
Imperial College Healthcare NHS Trust,  
London Professor of Practice  
(Cardiopulmonary Medicine),  
National Heart & Lung Institute,  
Imperial College London  
*London, UK*



**Prof. Olivier Sitbon, MD, PhD**  
Department of Respiratory and Intensive Care Medicine  
French National Referral Centre for Pulmonary Hypertension  
Hôpital Bicêtre, Paris-Saclay University  
*Le Kremlin-Bicêtre, France*



**Prof. David G. Kiely, BSc (Hons), MD, FRCP**  
Professor of Pulmonary Vascular Medicine  
Director of the Sheffield Pulmonary Vascular Disease Unit  
School of Medicine and Population Health  
*Sheffield, UK*



**Prof. Stephan Rosenkranz, MD**  
Interventional Cardiologist,  
Head, Pulmonary Hypertension (PH) Center,  
University of Cologne  
Head, Cologne Cardiovascular Research Center (CCRC)  
*Cologne, Germany*



**Prof. Marc Humbert, MD, PhD**  
Director of the Department of Respiratory and Intensive Care Medicine  
French Pulmonary Hypertension Reference Center  
Hôpital Bicêtre, Université Paris-Saclay  
Past President, European Respiratory Society  
*Le Kremlin-Bicêtre, France*



**Prof. Sean Gaine, MB, PhD, FRCPI**  
Consultant, Respiratory Physician  
Mater Misericordiae University Hospital  
Director, National Pulmonary Hypertension Unit  
*Dublin, Ireland*



**Prof. Irene M. Lang, MD**  
Clinical Cardiologist  
Professor of Vascular Biology  
Department of Cardiology  
AKH-Vienna, Medical University of Vienna  
*Vienna, Austria*



**Prof. H Ardeschir Ghofrani, MD**  
Professor, Pulmonary Vascular Research,  
Justus Liebig University, Giessen, Germany  
Head, Pulmonary Hypertension Division,  
Pulmonary Vascular Research Institute  
CEO, University Hospital Giessen and Marburg  
*Giessen, Germany*



**Prof. Zhi-Cheng Jing, MD, PhD**  
President – East Asian Society of Pulmonary Hypertension  
Professor of Medicine  
Head, Department of Cardiology  
Guangdong Cardiovascular Institute,  
Guangdong Provincial People's Hospital,  
Guangdong Academy of Medical Sciences  
*Guangzhou, China*



**Prof. Hiromi Matsubara MD, PhD**  
Director, Clinical Research  
Director, Department of Cardiology  
National Hospital Org., Okayama Medical Center  
Clinical Professor of Cardiovascular Medicine  
Graduate School of Medicine Dentistry and Pharmaceutical Sciences  
Okayama University  
*Okayama, Japan*




**Noura Alturaif, MD**  
Consultant, Pulmonary and Pulmonary Hypertension  
Lung Health Department  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*



**Prof. Paul B. Yu, MD, PhD**  
Director, Cardiovascular  
Research Center Cardiology Division  
Charles and Elizabeth Sanders Endowed Chair  
Massachusetts General Hospital  
Associate Prof. of Medicine, Harvard Medical School  
*Boston, USA*



**Prof. Soni Savai Pullamsetti, MD, PhD**  
Professor, Cardio Pulmonary Institute (CPI)  
Justus Liebig University  
*Giessen, Germany*



**Prof. Ioana R. Preston, MD**  
Consultant, Pulmonary and Critical Care Medicine  
Director, PH Program,  
Lahey Clinic and Medical Center  
*Burlington, Massachusetts, USA*



**Abdullah M. Alkhodair, MD, FRCPC**  
Chairman, Scientific Committee  
Consultant, Interventional Cardiology/  
Pulmonary Hypertension  
Adult Cardiology Program Director  
King Fahad Medical City  
*Riyadh, Saudi Arabia*



**Prof. Khodr Tello, MD**  
Head of Pulmonology, Respiratory and Intensive Care Medicine  
Northwest Hospital  
*Giessen, Germany*



**Prof. Jean-Luc Vachiéry, MD**  
Clinical Professor of Cardiology,  
Director, Pulmonary Vascular Diseases and Heart Failure Clinic,  
Hopital Universitaire de Bruxelles (H.U.B.)  
Erasmus  
*Brussels, Belgium*



**Prof. Majdy M. Idrees, MD, FRCPC, FPPVRI**  
Head, Pulmonary Vascular Unit  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**HQ Han, MD, PhD**  
Co-Founder and CEO, AliveGen  
*Thousand Oaks, CA, USA*



**Mona Alotaibi, MD**  
Assistant Clinical Professor Medicine  
University of California,  
San Diego - School of Medicine  
*San Diego, California, USA*



**Nawal Al Gubaisi, MD, SSC-Med, SF-PD**  
Consultant Pulmonologist  
Pulmonary Hypertension Specialist  
Head of Pulmonary Medicine Unit  
King Fahad Medical Military Complex  
*Dhahran, Saudi Arabia*





**Hassan M. Alnuaimat, MD**  
Consultant Staff Physician, Pulmonary and  
Critical Care Medicine,  
Director, Pulmonary Hypertension Program,  
Cleveland Clinic Abu Dhabi  
*Abu Dhabi, UAE*



**Ragdah H. Arif, MD, FRCPC, ABIM**  
Consultant, Pulmonologist and Pulmonary  
Hypertension  
Assistant Professor, King Abdulaziz  
University/Hospital  
*Jeddah, Saudi Arabia*



**Roberto Badagliacca, MD, PhD**  
Professor, Department of Cardiovascular and  
Respiratory Science  
School of Medicine  
University of Rome "Sapienza".  
*Rome, Italy*



**Khaled M. Alobaidellah, MD, FRCPC**  
Consultant Adult Pulmonary, Pulmonary  
Hypertension,  
Pulmonary Medicine division,  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**Ahmed Krimly, MD**  
Consultant, Adult Congenital  
Heart Disease and Interventional Cardiology,  
King Faisal Cardiac Centre,  
King Abdul Aziz Medical City  
*Jeddah, Saudi Arabia*



**Fayez K. Alahmadi, MD**  
Consultant, Pulmonary Medicine,  
Pulmonary Hypertension and Balloon  
Pulmonary Angioplasty,  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*



**Hani Sabbour, MD, FACC, FHRS, FASE**  
Consultant Cardiologist and Cardiac  
Electrophysiology  
Mediclinic  
*Abu Dhabi, UAE*



**Hussam M. Sakkijha, MD**  
Consultant, Pulmonary,  
Critical Care and Sleep Medicine  
King Fahad Medical City,  
*Riyadh, Saudi Arabia*



**Bader J. Alghamdi, MD**  
Consultant, Pulmonary Medicine, Pulmonary  
Hypertension, & Clinical Cardiopulmonary  
Exercise Testing  
Assistant Professor in King Saud bin Abdulaziz  
Uni. for Health Sciences (KSAU-HS)  
Section Head of Respiriology and Director of  
Respirology Fellowship Training Program,  
Ministry of National Guard  
*Jeddah, Saudi Arabia*



**Chih-Hsin Hsu, MD, PhD**  
President, Taiwan Society of Critical Care Medicine  
Professor of Medicine, College of Medicine,  
National Cheng Kung University  
Deputy Superintendent, National Cheng Kung  
Univeristy Hospital  
Director, Heart Failure and Pulmonary Hypertension  
Program, National Cheng Kung University Hospital  
*Tainan, Taiwan*



**Prof. John Feenstra, MBBS, FRACP, FCCP**  
President, Pulmonary Hypertension Society of  
Australia and New Zealand (PHSANZ)  
Thoracic Physician, Pulmonary Hypertension  
Specialist  
Visiting Medical Practitioner, Wesley and Prince  
Charles Hospitals  
Director of Pulmonary Hypertension Research &  
Senior Lecturer, University of Queensland  
*Queensland, Australia*



**Prof. Yoshihiro Fukumoto, MD, PhD, FJCC, FESC, FAHA, FJCS**  
President, Japanese Pulmonary Circulation and  
Pulmonary Hypertension Society  
Deputy Director of Kurume University Hospital  
Professor and Chairman, Division of  
Cardiovascular Medicine,  
Department of Internal Medicine  
Kurume University School of Medicine  
*Kurume, Japan*



**Badr Alzahrani, MD, FACC**  
Consultant Interventional Cardiology  
American Board of Internal medicine,  
Cardiology and Interventional Cardiology,  
Prince Sultan Cardiac Center  
*Riyadh, Saudi Arabia*



**Shaya A. Alshaya, MD**  
Consultant Adult Pulmonary, Pulmonary Hypertension  
Head, Adult Pulmonary department at King Fahad  
Medical City  
Head, Pulmonary Hypertension Clinical Program &  
Service at King Fahad Medical City  
Program Director, Internal Medicine Residency  
Program, Riyadh Second Health Cluster  
*Riyadh, Saudi Arabia*



**Ali O. Abualsaud, MBBS, FRCPC**  
Associate Professor of Medicine,  
McGill University, *Montreal, Canada*  
Consultant Interventional/Structural Cardiology  
and Adult Congenital Heart Disease  
King Fahad University Hospital  
Imam Abdulrahman Bin Faisal University  
*AlKhobar, Saudi Arabia*



**Lama A. Alabdi, PhD**  
Head Section, Developmental Genetics  
Department of Translational Genomics  
King Faisal Specialist Hospital &  
Research Centre  
*Riyadh, Saudi Arabia*



**Abdullah A. Al Masoud, MD**  
Consultant Cardiologist,  
Heart Center  
King Faisal Specialist Hospital & Research  
Centre  
*Riyadh, Saudi Arabia*



**Sarah K. Alrasheed, MD**  
Consultant Pulmonary Medicine,  
Pulmonary Hypertension and ILD  
King Faisal Specialist Hospital &  
Research Centre- Madina  
*Almadinah, Saudi Arabia*



**Saleh A. Aldammas, MD**  
Consultant, Pulmonary and Sleep Medicine  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*



**Mnahi Bin Saeedan, MD**  
Cardiothoracic Radiologist,  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*



# STREAMING

# LIVE




facebook




YouTube



Scan to Watch



*Tell a  
Friend*



## The Official Publication of Saudi Thoracic Society

**A leading Journal in  
Thoracic Medicine  
with an impact  
factor of 2.10**

- A peer review and open access journal
- Available in Pubmed
- Indexed in more than 30 searchengines
- Initial review by the board within a week
- Submission - Decision time is 45 days only
- No processing or publication fees
- A friendly free online submission system



[www.thoracicmedicine.org](http://www.thoracicmedicine.org)





## Comprehensive Multimodality Imaging Findings in PH/ CTEPH

Thursday, 12 February 2026 | Time: 3:00pm - 4:00pm

### Speaker:



**Mnahi Bin Saeedan, MD**  
Cardiothoracic Radiologist,  
King Faisal Specialist Hospital &  
Research Centre  
*Riyadh, Saudi Arabia*

### Chair & Discussant:



**Sarah K. Alrasheed, MD**  
Consultant Pulmonary Medicine,  
Pulmonary Hypertension and ILD  
King Faisal Specialist Hospital &  
Research Centre- Madina  
*Almadinah, Saudi Arabia*

### Objectives

The goal is to review the imaging findings of pulmonary hypertension with an emphasis on the role of computed tomography (CT) and to recognize the common dziseases in each pulmonary hypertension group.

### Structure:

- Presentation listing and showing the lung parenchyma, bronchial arteries, pulmonary arteries, and cardiac findings that can guide radiologists and clinicians to an appropriate diagnosis of different pulmonary hypertension groups.
- Interactive chest CT cases: Participants will access online scrollable CT images of different pulmonary hypertension cases to review them prior to having an open discussion.
- Case-based review: Selected images of different cases will be presented. Each case will have an online multiple choice question to be answered by the participants.

**\* Participants should bring a laptop, tablet, or smart phone for the interactive activities.**



## Right Heart Catheterization; State of the Art Measurements

Thursday, 12 February 2026 | Time: 4:00pm - 5:00pm

### Speaker:



**Prof. Stephan Rosenkranz, MD**  
Interventional Cardiologist,  
Head, Pulmonary Hypertension (PH) Center,  
University of Cologne  
Head, Cologne Cardiovascular Research Center  
(CCRC)  
*Cologne, Germany*

### Chair & Discussant:



**Abdullah A. Al Masoud, MD**  
Consultant Cardiologist,  
Heart Center  
King Faisal Specialist Hospital & Research  
Centre  
*Riyadh, Saudi Arabia*

### Objectives


To familiarize audience with basics of RHC, when to refer your patient, and how to interpret the numbers

### Outline:

In this interactive session, attendees will be updated on:

- Common indications, contraindications, and complications
- The basics of hemodynamics, how it correlates with echocardiogram
- The setup of the correct study
- Some pitfalls that will make results unreliable
- Making sense of the Right Heart Cath numbers
- Interactive Data interpretation





## Risk Stratification and Management; Case-Based Scenarios

Thursday, 12 February 2026 | Time: 5:00pm - 6:00pm

### Speaker:



**Prof. Sean Gaine, MB, PhD, FRCPI**  
Consultant, Respiratory Physician  
Mater Misericordiae University Hospital  
Director, National Pulmonary  
Hypertension Unit  
*Dublin, Ireland*

### Chair & Discussant:



**Nawal Al Gubaisi, MD, SSC-Med, SF-PD**  
Consultant Pulmonologist  
Pulmonary Hypertension Specialist  
Head of Pulmonary Medicine Unit  
King Fahad Medical Military Complex  
*Dhahran, Saudi Arabia*

### Objectives

To familiarise the audience with the use of risk stratification tools in clinical practice, how to integrate them into treatment decisions, when to use a simple, pragmatic approach, and when to consider a more personalised approach.

### Structure:

- Presentation of case-based scenarios in different forms of PAH.
- Interactive use of risk stratification tools.
- Multiple choice questions to be answered by the participants.
- Strengths and weaknesses of risk tools and their use in clinical practice
- Integration of risk tools in clinical trials (endpoint; enrichment...)

# We are global community

With a network of over 6,000 people in over a hundred countries, we are the only not-for-profit membership organisation dedicated entirely to enhancing research and education to combat pulmonary vascular disease on a global scale.

Being part of our global network means sharing a joint vision to reduce the global burden of pulmonary vascular disease.

All our members are dedicated to raising awareness of the condition - along with its causes and symptoms - and undertaking or facilitating basic, clinical and translational research at a level

that no single individual or academic institution could accomplish.

### How we work

- We **advocate** for pulmonary vascular disease to be well understood and properly resourced
- We **educate** healthcare professionals to improve diagnosis, treatment and care
- We **collaborate** globally to share knowledge and inspire cutting edge research

## Stronger together











DAY 1 - THURSDAY

12 FEBRUARY 2026

EVENING SESSION

**Pre-Conference Workshops**

- 15:00 - 16:00     **Comprehensive Multimodality Imaging Findings in PH/ CTEPH**  
Speaker:  Mnahi Bin Saeedan  
Chair & Discussant:  Sarah K. Alrasheed
- 16:00 - 17:00     **Right Heart Catheterization; State of the Art Measurements**  
Speaker:  Stephan Rosenkranz  
Chair & Discussant:  Abdullah A. Al Masoud
- 17:00 - 18:00     **Risk Stratification and Management; Case-Based Scenarios**  
Speaker:  Sean Gaine  
Chair & Discussant:  Nawal A. Al Gubaisi

DAY 1 - THURSDAY





12 FEBRUARY 2026

EVENING SESSION

**17:00 - 18:45     REGISTRATION**

- 18:45 - 19:00     **Welcome Notes**  
 Prof. Abdullah M. Aldalaan

**Session 1: Keynote**

- Chairs:**  Abdullah M. Alkhodair  Saleh A. Aldammas
- 19:00 - 19:30     **TGF- $\beta$  Super family and PDGF Pathways Story: Origins, Breakthroughs, and Future Direction**  
 Paul B. Yu
- 19:30 - 20:00     **PH: Year in Review, Key Milestones and Advances**  
 Husam M. Sakkijha
- 20:00 - 20:10     **Q & A Panel Discussion**

**20:10 - 20:30     SAPH International Collaborating Societies Greetings**



**Prof. Luke Howard, MD, DPhil, FRCP**  
PVRI Co-Lead, Innovative Drug Discovery Initiative



**Prof. Zhi-Cheng Jing, MD, PhD**  
President, East Asian Society of Pulmonary Hypertension



**Prof. Yoshihiro Fukumoto, MD, PhD, FJCC, FESC, FAHA, FJCS**  
President, Japanese Pulmonary Circulation and Pulmonary Hypertension Society



**Prof. Chih-Hsin Hsu, MD, PhD**  
President, Taiwan Society of Critical Care Medicine

**20:30 - 22:30     DINNER**

**END OF 1<sup>st</sup> DAY**



DAY 2 - FRIDAY

13 FEBRUARY 2026



MORNING SESSION


07:30 - 08:15 REGISTRATION

### Session 2: PAH Basic Science

Chairs:  Abdullah M. Aldalaan   Mona Alotaibi

08:20 - 08:40 **Unraveling the Genetic and Epigenetic Blueprint of PAH**  
 Soni Savai Pullamsetti

08:40 - 09:00 **Deep Phenotyping; Endophenotypes-Based Ontology**  
  Mona Alotaibi

09:00 - 09:20 **GDF2 Gene Mutation in High-Inbred Population with PAH**  
 Lama A. Alabdi

09:20 - 09:30 Q & A Panel Discussion

09:30 - 09:45 COFFEE BREAK

### Session 3: PAH Management ; TGF- $\beta$ Super Family Pathway


Chairs:  Stephan Rosenkranz  Ahmed Krimly

09:45 - 10:05 **Sotatercept in Newly Diagnosed PAH; Efficacy and Safety; (HYPERION Study)**  
 H. Ardeschir Ghofrani

10:05 - 10:25 **Sotatercept Longterm Efficacy & Safety in PAH; SOTERIA Study**  
 Ioana Preston

10:25 - 10:45 **Targeting the Activin Signaling Pathway in Cpc-PH due to HFpEF**  
 Jean-Luc Vachiéry

10:45 - 11:00 Q & A Panel Discussion

11:00 - 11:20 **Satellite Symposium**  
**Importance of the Assessment of RV-Function for the Management of PH Patients; What do we know about Riociguat?**  
 H. Ardeschir Ghofrani



11:20 - 13:30 PRAYER AND LUNCH BREAK

DAY 2 - FRIDAY


13 FEBRUARY 2026

AFTERNOON SESSION

### Session 4: Pulmonary Arterial Hypertension Treatment (Miscellaneous)

Chairs:  Roberto Badagliacca  Paul B. Yu

13:30 - 13:50 **Targeting Smad 2/3 Signaling Pathway; A Potential Therapeutic Molecule with less side effect (ALG-801)**  
 HQ Han

13:50 - 14:10 **Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with PAH**  
 Jean-Luc Vachiéry

14:10 - 14:30 **Insights from PATH-GCC: PAH Treatment Patterns and Outcomes Across the Gulf Countries**  
 Majdy M. Idrees

14:30 - 14:50 **Exploring Novel Targets for the Next Generation of PAH Therapies**  
 Marc Humbert

14:50 - 15:00 Q & A Panel Discussion

15:00 - 15:30 COFFEE BREAK

### Session 5: Challenging Real-life Cases

Chairs:  Shaya Al Shaya  Yoshihiro Fukumoto  Sean Gaine

15:30 - 15:50 **PAH with Catastrophic Course with the Whole Spectrum of Intervention**  
 Noura Alturaif

15:50 - 16:10 **A Rare Case of Subacute PAH**  
 Fayez K. Al Ahmadi

16:10 - 16:30 **Cough and "Severe ILD "; A Case of Unexplained Progressive Dyspnea**  
 Hani Sabbour

16:30 - 16:50 **Multifactorial Hemoptysis: A Case Unraveled.**  
 Ragdah Arif

END OF 2<sup>nd</sup> DAY







DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

**Session 6: Pulmonary Hypertension Management (Focus on Group III)**

**Chairs:**  Bader J. Alghamdi  Hassan M. Alnuaimat

- 09:00 – 09:20 **PH Associated with CLD; RHC- Based timely Diagnosis and Role of Screening in PH-ILD**  
 David Kiely
- 09:20 – 09:40 **PH- ILD; Contemporary Management**  
 Luke Howard
- 09:40 – 10:00 **Inhaled Seralutinib in PH-ILD Treatment; a Potential Two Targets in One**  
 Khodr Tello
- 10:00 – 10:20 **Tyrosine Kinase Inhibitors in PAH: a Double-Edged Sword**  
 Olivier Sitbon
- 10:20 – 10:30 **Q & A Panel Discussion**

**10:30 - 10:45 COFFEE BREAK**





DAY 3 - SATURDAY

14 FEBRUARY 2026

MORNING SESSION

**Session 7: CTEPH**

**Chairs:**  Bader Alzahrani  Khaled M. Alobaidellah

- 10:45 - 11:05 **Ten-year survival and prognostic factors after BPA in inoperable CTEPH**  
 Hiromi Matsubara
- 11:05 – 11:25 **Optimizing BPA Outcomes: An Update on The Role of Medical Therapy Pre- and Post-Procedure**  
 Irene Lang
- 11:25 – 11:45 **Enhancing the Diagnostic Approach to CTEPH**  
 David Kiely
- 11:45 – 12:10 **Balloon Pulmonary Angioplasty in Sickle Cell Disease with Chronic Thromboembolic Pulmonary Hypertension**  
 Ali Omar Abualsaud
- 12:10 – 12:20 **Q & A Panel Discussion**

**12:20 - 12:30 CLOSING REMARKS**

**12:30 - 13:30 LUNCH**

**END OF 3<sup>rd</sup> DAY**



## Community Calls

Informal monthly discussions with researchers talking about their newly published papers.

The Calls attract a diverse audience from countries across the world. Every month and everyone in the pulmonary hypertension community is invited to join.



Take part in our calls and webinars. They're freely available to everyone in the pulmonary hypertension community.

[pvrinstitute.org](http://pvrinstitute.org)



## PVRI 2024 Digital


Breaking barriers in pulmonary hypertension

PVRI monthly webinars feature keynote talks from senior experts in the field of pulmonary hypertension as well as young investigators. Each session offers ample time for Q&A to encourage active participation from the audience.

They take place on the second Wednesday of each month at 15:00 BST/ GMT and we would love to see you there.

## FACULTY PROFILE

**SAPH2026**  
THE 19<sup>TH</sup> ANNUAL CONFERENCE OF  
THE SAUDI ASSOCIATION FOR PULMONARY HYPERTENSION  
12-14 FEBRUARY 2026 | JEDDAH HILTON, SAUDI ARABIA



### Prof. Abdullah M. Aldalaan, MD

Chairman, the 19<sup>th</sup> Annual Conference of Saudi Association for Pulmonary Hypertension (SAPH2026)  
Chairman, Saudi Association for Pulmonary Hypertension (SAPH)  
Consultant, Pulmonary Medicine  
Director, Pulmonary Hypertension Program, Lung Health Center  
King Faisal Specialist Hospital & Research Centre  
Professor of Medicine, Alfaisal University  
*Riyadh, Saudi Arabia*

Prof. Abdullah M. Aldalaan graduated from King Saud University in Riyadh. He received his residency training at Duke University Medical Center in North Carolina, USA; and completed his fellowship training in Pulmonary and Critical Care at University of Virginia, USA. He obtained American Board of Internal Medicine, Pulmonary Medicine and Critical Care Medicine. Since then, he has been practicing as a Pulmonologist and Intensivists at King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia.

He established the Lung Transplant Program in 2003 and the Pulmonary Hypertension Program at King Faisal Specialist Hospital & Research Centre. The Pulmonary Hypertension Program is the main program in the area which provides comprehensive diagnostic and therapeutic protocols for patients with pulmonary hypertension, which includes all available internationally recognized medical interventions in this field.

In addition to his clinical responsibilities, he held administrative positions such as Section Head of Pulmonary Medicine, Department of Medicine; Director Pulmonary Fellowship program- Lung Health Center, Director of Ambulatory Care Services. His main area of interest is Pulmonary Hypertension. He established and still runs the Saudi Pulmonary Hypertension Registry from which the analysis of the clinical characteristics and outcome of PH patients among Saudi Citizens was published; also, the first incidence of genetic mutations in Saudi patients with pulmonary hypertension has also been published.

Within the Pulmonary Hypertension Program, he also runs a comprehensive CTEPH management program including medical as well as pulmonary endarterectomy treatments. His research interest is focused on Pulmonary Hypertension where he published several papers. He was awarded recognition awards at KFSH&RC for his work and research on Pulmonary Hypertension.

In addition to his clinical role, he is also Professor of Medicine at the prestigious institution, Alfaisal University, Riyadh, Saudi Arabia



### Prof. Marc Humbert, MD, PhD

Director of the Department of Respiratory and Intensive Care Medicine  
French Pulmonary Hypertension Reference Center  
Hôpital Bicêtre, Université Paris-Saclay  
Past President, European Respiratory Society  
*Le Kremlin-Bicêtre, France*

Past President, of the European Respiratory Society, Marc Humbert, MD, PhD, is Professor of Respiratory Medicine, Vice Dean for Research and Director of the Inserm Unit 999 at the Université Paris-Saclay Faculty of Medicine in Le Kremlin-Bicêtre, France. He is the Director of the Department of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Centre and Severe Asthma Clinic, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France.

Marc Humbert was the Chief Editor of the European Respiratory Journal from 2013 to 2017 and he is currently Section Editor in charge of Pulmonary Vascular Medicine. He is a Fellow of the European Respiratory Society (ERS Foundation Fellow) and has received several distinctions including the Cournand Lecture Award, the Rare Disease Award of the Fondation de France, and the ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension. Since 2017, Marc Humbert is the vice-coordinator of the European Reference Network for rare and low prevalence respiratory diseases (ERN-LUNG). Clarivate Analytics listed Marc Humbert as one of the world's highly cited researchers in the field of Clinical Medicine.





**Prof. Luke Howard, MD, DPhil, FRCP**  
Consultant Pulmonologist, Hammersmith Hospital,  
Imperial College Healthcare NHS Trust,  
London Professor of Practice (Cardiopulmonary Medicine),  
National Heart & Lung Institute, Imperial College London  
*London, UK*

Dr. Luke Howard is a consultant respiratory physician who specializes in cardiopulmonary medicine and exercises physiology. He specializes in diseases of the pulmonary circulation, in particular, Pulmonary Hypertension and pulmonary embolism, and through his interest in exercise physiology has specific expertise in unexplained breathlessness. He works in close collaboration with his colleagues in cardiology, rheumatology, and hematology to provide a comprehensive assessment of conditions leading to exercise limitation.

He consults for patients and athletes alike and has close links with the GB Rowing Team. He undertook his undergraduate training at the University of Oxford where he also completed his doctorate in altitude physiology and then his clinical training at the University of Cambridge, qualifying in 1996.

He trained in London and Cambridge, being appointed to the National Pulmonary Hypertension Service at Hammersmith Hospital in 2006 as a consultant with an honorary senior lecturer position at the National Heart and Lung Institute, Imperial College London. His research interests include iron physiology, cardiopulmonary hemodynamics, exercise physiology, Pulmonary embolism, and remote patient monitoring.



**Prof. Sean Gaine, MB, PhD, FRCPI**  
Consultant, Respiratory Physician  
Mater Misericordiae University Hospital  
Director, National Pulmonary Hypertension Unit  
*Dublin, Ireland*

Prof. Sean Gaine, is Consultant Respiratory Physician at Mater Misericordiae University Hospital in Dublin. He graduated from Trinity College Dublin and completed his residency and fellowship training at the Johns Hopkins Hospital, Baltimore, USA. He subsequently held faculty positions at the Johns Hopkins Hospital, and at the University of Maryland School of Medicine. He established the Pulmonary Hypertension Center at the Johns Hopkins Hospital and subsequently the National Pulmonary Hypertension Unit in Dublin.

Professor Gaine was awarded the Samuel P. Asper Award for Achievement in Advancing International Medical Education from the Johns Hopkins Medical and Surgical Association. He previously served on the ERS/ESC Pulmonary Hypertension Guideline Committee. Prof. Gaine served as Chief Medical Officer of the Olympic Council of Ireland and led the medical team at the Olympic Games in Athens, Beijing, London and Rio.



**Prof. Olivier Sitbon, MD, PhD**  
Department of Respiratory and Intensive Care Medicine  
French National Referral Centre for Pulmonary Hypertension  
Hôpital Bicêtre, Paris-Saclay University  
*Le Kremlin-Bicêtre, France*

Olivier Sitbon, MD, PhD, FERS, is Professor of Respiratory Medicine at Université Paris-Saclay and a consultant at the French Referral Center for Pulmonary Hypertension (PH), Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre in Le Kremlin-Bicêtre, France. He is the current secretary of the ERS Assembly 13 on pulmonary vascular diseases and has been elected chair of this Assembly from September 2024.

Professor Sitbon has conducted extensive research in Pulmonary Arterial Hypertension (PAH) and he is the scientific leader of the French PH Registry. His investigational activities include clinical studies on factors associated with PAH, identification of prognostic factors, studies on risk stratification and treatment goals in PAH, and the development of new strategies for the treatment of PAH.

He was involved in every World PH Symposia over the past two decades and is currently co-chairing the PAH Treatment Algorithm Working Group of the 7th World Symposium on PH in 2024. He was a task force member and section editor of the 2022 ESC-ERS Guidelines for the diagnosis and treatment of PH. He has authored more than 420 peer-reviewed articles on PH and related topics in New England Journal of Medicine, Lancet Respiratory Medicine, Circulation, Journal of the American College of Cardiology, American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal, amongst other scientific journals.



**Prof. Irene M. Lang, MD**  
Clinical Cardiologist  
Professor of Vascular Biology  
Department of Cardiology  
AKH-Vienna, Medical University of Vienna  
*Vienna, Austria*

Irene Marthe Lang is a senior staff member at the Department of Cardiology, and Deputy Chair of the Department, at the Medical University of Vienna, Vienna, Austria. She carried out her medical education and residency at the University of Vienna, before taking on a 5-year postdoctoral research fellowship at the University of California, CA, USA, which included a joint appointment with the Scripps Research Institute, La Jolla, CA.

She has been a Professor of Vascular Biology at the Medical University of Vienna since 2004, where she leads a clinical and experimental group in vascular medicine focussing on pulmonary vascular biology and right ventricular function. She directs an outpatient unit for pulmonary vascular disease at the Medical University of Vienna. She is an active interventional and structural cardiologist, recently very active as balloon pulmonary angioplasty interventionist, and an active researcher.

She was nominated by the World Medical Association as a 'Caring Physician of the World' in 2006, 'Teacher of the Year' at MUV in 2013, and is past president of the Austrian Society of Cardiology. In April 2016, she was awarded the Großes Ehrenzeichen der Republik Österreich and an honorary doctorate from the University of Cyril and Methodius in Skopje, Macedonia. She is part of the International CTEPH Association (ICA) whose objectives are to increase awareness for CTEPH, foster worldwide collaboration between CTEPH centers, serve as platform for surgical centers and facilitate training of emerging CTEPH centers, as well as to advance research and education in CTEPH.



**Prof. David Kiely, MD, FRCP**  
Professor of Pulmonary Vascular Medicine  
Director, Sheffield Pulmonary Vascular Disease Unit  
Sheffield Teaching Hospitals NHS  
*Sheffield, UK*

David is a consultant respiratory physician and is a Professor of Pulmonary Vascular Medicine at the University of Sheffield. He was appointed as the Director of the Sheffield Pulmonary Vascular Disease Unit in 2001. David is the Chief Investigator of the ASPIRE Registry, a PVRI Imaging Task Force Leader and member of the 2022 ESC/ERS PH Guidelines and 7th WSPH Imaging Task Force. His research encompasses the diagnosis and assessment of pulmonary hypertension with a focus on imaging. He has participated in research funded by the NIHR, BHF, Wellcome Trust and MRC.



**Prof. H. Ardeschir Ghofrani, MD**  
Professor, Pulmonary Vascular Research, Justus Liebig University, Giessen, Germany  
Head, Pulmonary Hypertension Division, Pulmonary Vascular Research Institute  
CEO, University Hospital Giessen and Marburg  
*Giessen, Germany*

Hossein A. Ghofrani received his medical degree from the Medical School at Giessen University in Germany. He is Professor for Internal Medicine at University Hospital Giessen and Marburg GmbH. He currently is Head of the Pulmonary Hypertension Division, Department of Internal Medicine, at Giessen. He also leads a collaborative group on Cardiopulmonary Vascular System research. In addition, he is Director of Pneumology at the Kerckhoff Heart and Lung Center in Bad Nauheim, Germany.

Prof. Ghofrani has participated in the therapeutic development of surfactant for the treatment of acute respiratory distress syndrome (ARDS); prostanooids, PDE inhibitors, combination therapies, and soluble guanylate cyclase activators and stimulators for pulmonary hypertension; endothelin antagonists for chronic lung disease and pulmonary hypertension; and tyrosine kinase inhibitors for pulmonary vascular diseases. He has received four awards for investigations in pulmonary vascular science and is a reviewer for several medical scientific journals including the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Circulation, and Lancet.





**Prof. Stephan Rosenkranz, MD**

Interventional Cardiologist,  
Head, Pulmonary Hypertension (PH) Center, University of Cologne  
Head, Cologne Cardiovascular Research Center (CCRC)  
*Cologne, Germany*

Stephan Rosenkranz, MD, is an interventional cardiologist, and serves as the Head of the Pulmonary Hypertension Center at the University of Cologne, Germany, and also leads the Cologne Cardiovascular Research Center (CCRC). Professor Rosenkranz graduated from the Justus Liebig University in Giessen, Germany, before becoming a resident physician and research fellow at the University of Cologne. Following his doctoral degree, he undertook a post-doctoral fellowship at Harvard Medical School, USA, before returning to Cologne. He is currently the past-chair of the Working Group “Pulmonary Circulation and Right Ventricular Function” of the European Society of Cardiology (ESC), and is currently chair of the “Committee on Lung, Sleep & Pulmonary Hypertension” of the Heart Failure Association (HFA) of the ESC. He also served as task force chair of the 2022 ESC/ERS guidelines for pulmonary hypertension. His research interests include cardiopulmonary interaction and right ventricular function in left heart disease, and signal transduction and the biological importance of receptor tyrosine kinases and stress signaling in cardiovascular disease. He has been involved in many clinical trials in the fields of vascular disease/atherosclerosis, heart failure and pulmonary hypertension, and has received numerous scientific awards.



**Prof. Zhi-Cheng Jing, MD, PhD**

President – East Asian Society of Pulmonary Hypertension  
Professor of Medicine  
Head, Department of Cardiology  
Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital,  
Guangdong Academy of Medical Sciences  
*Guangzhou, China*

Dr. Zhi-Cheng Jing is Tenured Professor of Medicine and, the Head of Cardiology Department, Director of Key Lab of Pulmonary Vascular Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy Medical Sciences. Dr. Jing obtained his medical degree in 1994 from WeiFang Medical College, PhD degree in 1998 from Peking Union Medical College, China, before participating in 2-year postdoctoral training at the Hospital Antoine Bécclère in Paris-Sud Université, Clamart, France.

Dr. Jing has organized the genetics study on pulmonary hypertension and pulmonary embolism since 1999. He is the founder of BMP9 mutation in Asian patients with idiopathic pulmonary arterial hypertension. He has launched the Balloon Pulmonary Angioplasty and the PEA surgical therapy in CTEPH patients and organized the registry study for both paediatric and adult Pulmonary Hypertension and CTEPH in China. Dr. Jing and colleagues have joined most of the major clinical trials of new drugs for pulmonary hypertension, including leading the EVALUTION study of Vardenafil and FREEDOM study of oral Treprostinil. He also conducted a study on the association between lower socioeconomic status and outcomes in pulmonary hypertension. Dr. Jing has developed most of the referral centres for pulmonary vascular disease in China, and set up a collaborative network for these centres and provides training for hundreds of specialists in this area. He was also one of the initiators of East Asia Society of Pulmonary Hypertension. Among his outstanding achievements, Dr. Jing received the ‘Yangtze River Scholars Distinguished Professorship’ in 2014, The National Scientific Funding for Outstanding Young Scientist in 2014, Chinese Physician Prize 2018 (the national top prize and honour for clinician in China) - all above grants and funding are the most prestigious scientific funding in China. To date, he has published more than 250 peer-reviewed academic papers in both Chinese and international academic journals, and is the Associate Editor of Journal of Thrombosis and Haemostasis, European Respiratory Review, Internal Medicine and Emergency, Chinese Medicine Journal (English version) and the Chinese Journal of Cardiology. Dr. Jing is a member of the editorial board of the European Respiratory Journal and Annals of the American Thoracic Society. He was also elected as the President of Beijing Society of Thrombosis and Haemostasis in 2014.



**Abdullah M. Alkhodair, MD, FRCPC**

Chairman, Scientific Committee  
Consultant, Interventional Cardiology/Pulmonary Hypertension  
Adult Cardiology Program Director, King Fahad Medical City  
*Riyadh, Saudi Arabia*

Dr. Abdullah Alkhodair is a consultant in interventional cardiology, Structural heart diseases and Pulmonary Hypertension and the adult Cardiology program director at King Fahad Medical City, Riyadh, Saudi Arabia. He graduated with honors from King Saud University, Riyadh. He completed his Internal medicine and cardiology training in Canada and holds the American Board of Internal Medicine, and Cardiovascular diseases, and is certified by the Royal College of Physicians and Surgeons of Canada Certificate in internal medicine and Cardiology. He did a fellowship in pulmonary hypertension followed by interventional and structural heart disease fellowship at the University of British Columbia. He has over 15 publications in high impact journals.



**Prof. Hiromi Matsubara MD, PhD**

Director, Clinical Research  
Director, Department of Cardiology, National Hospital Org., Okayama Medical Center  
Clinical Professor of Cardiovascular Medicine  
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University  
*Okayama, Japan*

Hiromi Matsubara is presently working at National Hospital Organization, Okayama Medical Center as a Director in Department of Cardiovascular and Department of Clinical Science and Chair of the Research Ethics Committee. He is also a Clinical Professor at Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences in the department of Cardiovascular Medicine.

He has completed his MD at Okayama University Medical School and PhD at Okayama University Graduate School of Medicine and Dentistry. He has 117 SCI-Publications, 28 Standard publications as first or senior author under his accomplishments and many more. His interests are mainly on clinical and physiological aspects of pulmonary hypertension. He has experienced about 2100 procedures of Balloon Pulmonary Angioplasty (BPA) in more than 370 patients during past 14 years.



**Prof. Khodr Tello, MD**

Head of Pulmonology, Respiratory and Intensive Care Medicine  
Northwest Hospital  
*Giessen, Germany*

Prof. Khodr Tello is a leading specialist in pulmonology and respiratory medicine and serves as Chief Physician of the Department of Pulmonology and Respiratory Medicine at Krankenhaus Nordwest. Since April 2025, he has also been a key member of the leadership team of the hospital’s certified Lung Cancer Center, where he plays a central role in advancing modern, patient-centered lung cancer care.

With a strong focus on precision medicine, Prof. Tello is deeply committed to individualized diagnostics and therapy planning. His clinical and scientific work reflects the major advances in lung cancer treatment, particularly in the management of non-small cell lung cancer, where targeted therapies and molecular approaches have transformed advanced-stage disease into a manageable chronic condition for many patients. A core principle of his work is comprehensive diagnostics, including detailed histological and molecular tumor characterization, which forms the foundation for personalized treatment strategies.

Prof. Tello is a strong advocate of interdisciplinary collaboration. Under his leadership, the Department of Pulmonology works closely with thoracic surgery, oncology and hematology, cardiology, neurology, and radiology to ensure that each patient benefits from a holistic, evidence-based approach. Advanced diagnostic techniques such as bronchoscopy with endobronchial ultrasound, cryobiopsy, PET-CT imaging, and CT-guided biopsies are integral parts of the diagnostic pathway he has helped shape.

Through his commitment to teamwork, innovation, and state-of-the-art diagnostics, Prof. Khodr Tello has established himself as a key figure in modern lung cancer care, dedicated to improving outcomes and quality of life for patients through precision medicine and interdisciplinary excellence.



**Prof. John Feenstra, MBBS, FRACP, FCCP**

President, Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ)  
Thoracic Physician, Pulmonary Hypertension Specialist  
Visiting Medical Practitioner, Wesley and Prince Charles Hospitals  
Director of Pulmonary Hypertension Research & Senior Lecturer, University of Queensland  
*Queensland, Australia*

Dr. John Feenstra graduated from the University of Queensland Medical School in 1996 and completed his advanced training in thoracic and sleep medicine in Brisbane. He has completed two fellowship years, one in Sleep Disorders, and the other in Pulmonary Hypertension and Lung Transplant.

Dr. Feenstra has been in private practice since 2008 at the Wesley Hospital. In 2008, he established the Welsey Pulmonary Hypertension Unit to provide assessment and management of pulmonary hypertension. A senior lecturer of Medicine with UQ, Griffith and Bond Universities, Dr. Feenstra is also the academic lead for medicine at the UnitingCare Health Clinical School.





**Prof. Jean-Luc Vachiéry, MD**

Clinical Professor of Cardiology,  
Director, Pulmonary Vascular Diseases and Heart Failure Clinic,  
Hopital Universitaire de Bruxelles (H.U.B.) Erasme  
*Brussels, Belgium*

Jean-Luc Vachiéry is a Clinical Professor of Cardiology and a Director of the Pulmonary Vascular Diseases and Heart Failure Clinic at the Hopital Universitaire de Bruxelles (H.U.B.) Erasme, Belgium. He received his board certification in Internal Medicine in 1992 and in Cardiology in 1995. He has authored several articles, book chapter and participated in many collaborative research projects. This led to the creation of a clinical unit dedicated to Patient Management and clinical research in Pulmonary Hypertension and heart failure in 2008.

He has co-chaired the Pulmonary Hypertension Council at the International Heart and Lung Society (2002 - 2005), the Working Group on Pulmonary Circulation and Right Ventricular Function at the European Society of Cardiology (2006 - 2008) and the Working Group on Heart Failure at the Belgian Society of Cardiology (2008 - 2008). He was a Task Force member and section editor of the European Guidelines on Pulmonary Hypertension (2009 and 2015).

He is the current chair of the PH Council at the ISHLT (2018 - 2020). He has also been involved in the World Symposium on Pulmonary Hypertension as task force member in 2003, (co-chair of the PH due to heart and lung diseases task force) 2013 and was the co-chair of the Task Force on Pulmonary Hypertension due to left heart diseases for the upcoming World Symposium on Pulmonary Hypertension in 2018. He acts as an expert for several regulatory agencies and Scientific Organizations for matters related to medicines for Pulmonary Hypertension



**HQ Han, MD, PhD**

Co-Founder and CEO, AliveGen  
*Thousand Oaks, CA, USA*

HQ Han, MD, PhD, is an accomplished leader in drug discovery and innovation in the field of metabolic disorders and muscle wasting diseases. He founded AliveGen in 2014 and has been serving as its president and CEO. Prior to AliveGen, Dr. Han spent 17 years at Amgen, where he held positions with increasing responsibilities in R&D including scientific executive director and head of muscle unit. He spearheaded new therapeutic initiatives and R&D strategies on muscle wasting diseases at Amgen and led teams to successfully advance multiple novel clinical candidates from lab bench to clinical development. He also served as a PI for NASA life science and led multinational team efforts to explore countermeasures for spaceflight-induced muscle atrophy and bone loss. As the scientific founder, Dr. Han contributed significantly to the formation of Atara Biotherapeutics, Inc., now a publicly traded company. Prior to joining Amgen, he served on the faculty of The Rockefeller University as an assistant professor. He received his doctoral degree in molecular and cellular neuroscience under the guidance of Nobel laureate Prof. Paul Greengard at The Rockefeller University and his postdoctoral fellowship training under the supervision of Prof. Alfred Goldberg at Harvard Medical School. He is an inventor of many therapeutic patents and has published articles in Cell, Nature and Science.



**Faye K. Alahmadi, MD**

Consultant, Pulmonary Medicine,  
Pulmonary Hypertension and Balloon  
Pulmonary Angioplasty, King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*

Dr. Faye Alahmadi is a consultant, adult pulmonary medicine section at King Faisal Specialist Hospital and Research Centre. He has completed his clinical fellowship training in balloon pulmonary angioplasty at National Hospital Organization Okayama Medical Center in Okayama, Japan and clinical fellowship in pulmonary hypertension at Vancouver General Hospital at the University of British Columbia in Vancouver, Canada. He had received certificates on clinical fellowship in balloon pulmonary angioplasty, Japan 2021, clinical fellowship in pulmonary hypertension, Canada 2020 and Saudi board of respiratory Medicine, 2019.

Dr. Faye Alahmadi have attended several conferences including SAPH 2021 virtual and presented a presentation about “Idiopathic Pulmonary Arterial Hypertension in Pregnancy” in the 12th annual conference of the Saudi Association for Pulmonary Hypertension (SAPH 2019), Bahrain 2019. He presented a poster “King Faisal Specialist Hospital & Research Centre CTEPH experience” in the European pulmonary hypertension conference, Vienna 2018. He has completed four research works including “Does community size or commute time affect severity of illness at diagnosis or quality of care in a centralized care model of pulmonary hypertension” which was published at International Journal of Cardiology, March 2021.



**Prof. Majdy M. Idrees, MD, FRCPC, FPVRI**

Head, Pulmonary Vascular Unit  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*

Majdy Idrees is an Adjunct Professor of Pulmonary Medicine at the University of British Columbia, Vancouver, Canada and the Former Head of Pulmonary Division and the Director of the Pulmonary Vascular Disease Unit at Prince Sultan Military Medical City (Armed Forces Hospital), Riyadh, Saudi Arabia. He was the first to establish the nucleus of pulmonary vascular diseases/pulmonary hypertension medicine in the Arab Gulf countries and is the founder, and the former head, of the Saudi Association for Pulmonary Hypertension.

He received his MBBS degree from King Saud University in Riyadh, Saudi Arabia, and did his postgraduate training in both Internal Medicine and Pulmonary Medicine at the University of British Columbia, Canada from 1992 – 1997. He had his American Board degree in Pulmonary Medicine in 1996, and the Canadian Board in Pulmonary Medicine in 1997. His major area of research is related to pulmonary hypertension and pulmonary vascular diseases, and also to airways diseases. He has more than 50 publications in peer reviewed journals that include book chapters, original papers, and review articles.

He is the primary author of the Saudi Guidelines for the management of Pulmonary Hypertension and a coauthor of the Saudi Guidelines in both Asthma and COPD. He is a manuscript reviewer and co-editor of many medical journals. He was awarded and recognized for his achievements in the field of pulmonary vascular diseases by the Pulmonary Vascular Research Institute, and his name was added to the “Pulmonary Hypertension Committee of Honor” chosen by the Spanish Ministry of Health. He has been invited as a guest speaker in many national and International meetings and gave more than 450 lectures in different fields of pulmonary medicine.



**Prof. Ioana R. Preston, MD**

Consultant, Pulmonary and Critical Care Medicine  
Director, PH Program, Lahey Clinic and Medical Center  
*Burlington, Massachusetts, USA*

Dr. Ioana Preston is a pulmonologist in Boston, MA and is Associate Professor of Medicine at Tufts University School of Medicine. She is affiliated with Tufts Medical Center and Lowell General Hospital. She received her medical degree from

Carol Davila University of Medicine and Pharmacy and has been in practice 22 years. She is the Director of the Pulmonary Hypertension Center at Tufts Medical Center in Boston.

**Education & Training**

Brown University Fellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2002  
Brown University Fellowship, Pulmonary Disease and Critical Care Medicine, 1999 - 2001  
Brown University Residency, Internal Medicine, 1997 - 1999  
Cleveland Clinic Foundation/Fairview Hospital Internship, Internal Medicine, 1996 - 1997

**Certifications & Licensure**

MA State Medical License 2001 - 2024  
RI State Medical License 1998 - 2012  
American Board of Internal Medicine- Critical Care Medicine & Pulmonary Disease

Her publications include “The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension” And “Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement from the American Heart Association”



**Nawal Al Gubaisi, MD, SSC-Med, SF-PD**

Consultant Pulmonologist  
Pulmonary Hypertension Specialist  
Head of Pulmonary Medicine Unit, King Fahad Medical Military Complex  
*Dhahran, Saudi Arabia*

Dr. Nawal Al Gubaisi is a Pulmonary Hypertension Consultant. She is currently the Head of Pulmonary Medicine Unit. King Fahd Medical Military Complex in Dhahran Saudi Arabia. She did her Pulmonary Hypertension and Right Heart Cath training in the University of British Columbia Vancouver Canada. She got a HERMES European Diploma and a Saudi Board in Respiratory Medicine. She is a consultant pulmonologist with several publications.





**Prof. Paul B. Yu, MD, PhD**

Director, Cardiovascular, Research Center Cardiology Division  
Charles and Elizabeth Sanders Endowed Chair, Massachusetts General Hospital  
Associate Prof. of Medicine, Harvard Medical School  
*Boston, USA*

Prof. Yu's laboratory studies the role of cytokine growth factor signaling in cardiovascular homeostasis, injury repair, and regeneration. Specifically, the laboratory has devised novel models, molecular tools, and pharmacologic probes for examining the function of bone morphogenetic protein (BMP), activin, growth and differentiation factor (GDF), and transforming growth factor-beta (TGF- $\beta$ ) signaling in cardiovascular and musculoskeletal development and function. A major focus of his laboratory's work is to discern how BMP/TGF- $\beta$  signaling achieves spatio-temporal and functional specificity for developmental patterning, and to modulate the tissue-specific consequences of inflammation and injury.

Prof. Yu's clinical and translational interests including pulmonary vascular disease, cardiovascular rheumatology, and fibrodysplasia ossificans progressive Prof. Paul Yu is Director of the Cardiovascular Research Center (CVRC) at Massachusetts General Hospital, recipient of the Charles Addison Sanders and Elizabeth Ann Sanders Endowed Chair, Associate Professor of Medicine at Harvard Medical School, and Physician in Cardiovascular Medicine at Massachusetts General Hospital (MGH).

Prof. Yu completed his AB in Philosophy and a BS in Biological Sciences at Stanford University, MD and PhD (Immunology) degrees at Duke University, completed Internal Medicine residency at UCSF, clinical and research fellowships in cardiovascular disease at MGH, and is board certified in Cardiovascular Medicine. Following a postdoctoral fellowship in cardiovascular biology with Prof. Kenneth Bloch, Prof. Yu established his independent laboratory at MGH in 2007, joined a collaborative basic and translational research effort in pulmonary arterial hypertension at BWH in 2011, and has returned to MGH in 2022 as Director of the CVRC.



**Prof. Soni Savai Pullamsetti, MD, PhD**

Professor, Cardio Pulmonary Institute (CPI)  
Justus Liebig University  
*Giessen, Germany*

Soni Savai Pullamsetti is a professor at the Cardio Pulmonary Institute (CPI) of Justus Liebig University in Giessen, Germany, where she leads the research group "Lung Vascular Epigenetics". She also leads a group for "Molecular Mechanisms of Pulmonary Vascular Diseases" at the Max Planck Institute for Heart and Lung Research (MPI-HLR), Bad Nauheim, Germany. The focus of Prof. Pullamsetti's lab is centered on understanding how epigenetic mechanisms and transcription factors impact gene regulation so that this information can potentially be used to develop new therapeutic strategies for lung diseases esp. pulmonary hypertension, right heart failure and pulmonary fibrosis. Recently she received prestigious European Research Council (ERC) consolidator grant to understand the developmental origins of pulmonary hypertension.

Soni Pullamsetti was born in Andhra Pradesh, India. She received her undergraduate degree from Osmania University, and Master of Science in Biotechnology from Central University, India. In 2002, she moved to Germany to pursue her PhD and Postdoctoral training at Justus Liebig University, Giessen. From 2011, she is appointed as an independent group leader in the Department of Lung Development and Remodeling at the MPI-HLR, Bad Nauheim, Germany. From 2014, she headed the German Lung Center (DZL) junior research group for pulmonary hypertension. From 2020, she has been appointed as a Full Professor at the Justus Liebig University, Giessen, Germany.

Prof. Dr. Pullamsetti serves as an area leader in the "Excellence Cluster for Cardio Pulmonary System (CPI)", a program committee member of the American Thoracic Society (ATS), American Heart Association (AHA) 3 CPR council, as an adjunct faculty of Institute for Lung Health (ILH), project leader and member of German Lung Center (DZL), and collaborative research center on lung diseases (UGMLC). Prof. Dr. Pullamsetti published in well-renowned scientific journals such as Nature Medicine, Science Translational Medicine, Journal of Clinical Investigation, American Journal of Respiratory and Critical Care Medicine, Circulation Research, International Journal of Cardiology and EMBO molecular medicine (Publications list Pullamsetti). She serves as a reviewer for well-renowned scientific journals and numerous national and international funding agencies. Currently she is serving at the editorial board of AJP-Lung, Scientific Reports and Pulmonary Vascular Research Institute (PVRI). She has received various national and international awards for her scientific accomplishments such as Romain Pauwels Research Prize (from European Respiratory Society (ERS)), Research Excellence Award (from German Respiratory Society) and Investigator Award at 5th World Symposium on PH.



**Mnahi Bin Saeedan, MD**

Cardiothoracic Radiologist,  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*

Dr. Mnahi Bin Saeedan is currently a Cardiothoracic radiologist at the King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia (01/2021-present).

He completed his graduation of Bachelor of Medicine and Bachelor of Surgery (MBBS) from the King Saud University College of Medicine, Riyadh, Saudi Arabia in the period of 09/2004-06/2010.

Postgraduate Education and Training:

- Cardiovascular imaging fellow, Cleveland Clinic, Cleveland, Ohio, USA, 12/2019-12/2020
- Thoracic imaging fellow, Cleveland Clinic, Cleveland, Ohio, USA, 12/2018-12/2019
- Cardiothoracic radiology fellow, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia, 10/2017-12/2018
- Radiology resident at KFSH&RC, Riyadh, Saudi Arabia, 10/2013-09/2017. Saudi Board of Diagnostic Radiology granted by Saudi Commission for Health Specialties, 11/2017
- Master of Public Health (MPH) - University of Miami, USA, 08/2012-08/2013
- One year internship with excellent performance in King Saud University hospitals and the affiliated hospitals, Riyadh, 07/2010- 06/2011

Awards:

- Resident of the Year, Radiology Residency Program, King Faisal Specialist Hospital and Research Centre, Riyadh, 2015- 2016
- Dean's Award for academic performance on medical school (average 4.42/5), 2010



**Abdullah A. Al Masoud, MD**

Consultant Cardiologist,  
Heart Center, King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*

Dr. Abdullah AlMasoud is a board-certified interventional cardiologist with extensive expertise in coronary, peripheral vascular, and structural heart interventions. Since January 2025, he has served as Chair of the Department of Adult Cardiology's Morbidity and Mortality Committee and has led the successful establishment of the interventional Balloon Pulmonary Angioplasty (BPA) procedure at King Faisal Specialist Hospital.

Dr. AlMasoud's clinical practice is supported by a strong outcomes-driven research interest and proficiency in complex cardiovascular procedures, including transcatheter aortic valve replacement (TAVR), left atrial appendage (LAA) occlusion, transcatheter edge-to-edge repair (TEER) for mitral valve disease, congenital heart interventions, and peripheral vascular therapies.

Dr. AlMasoud actively contributes to a progressive, academically driven healthcare environment that values collaboration, quality improvement, and innovation. He is dedicated to advancing institutional programs, enhancing clinical standards, and fostering professional growth among multidisciplinary teams.



**Sarah K. Alrasheed, MD**

Consultant Pulmonary Medicine, Pulmonary Hypertension and ILD  
King Faisal Specialist Hospital & Research Centre- Madinah  
*Almadinah, Saudi Arabia*

Dr. Sarah Khalid Alrasheed is a consultant pulmonologist with subspecialty expertise in interstitial lung disease and pulmonary hypertension. She earned her medical degree from Taibah University, completed internal medicine training and an adult pulmonary medicine fellowship at King Abdulaziz Medical City-National Guard in Riyadh, and pursued advanced training in ILD and PH at McMaster University's Firestone Institute for Respiratory Health. At King Faisal Hospital & Research Centre-Madinah, she provides comprehensive care for complex respiratory patients, with a focus on early diagnosis, multidisciplinary management, and improving patient outcomes.





**Mona Alotaibi, MD**

Assistant Clinical Professor Medicine  
University of California, San Diego - School of Medicine  
*San Diego, California, USA*

Mona Alotaibi, MD, is a board-certified pulmonologist and critical care physician who specializes in treatment of pulmonary vascular disease, including chronic thromboembolic pulmonary hypertension (CTEPH). Her clinical and research interests include investigating conditions that disturb or disrupt the normal order of the body and metabolic processes that contribute to the development of pulmonary vascular diseases.

As an associate professor of medicine at UC San Diego School of Medicine, she trains medical students, interns, residents and fellows. She leads studies that leverage diverse approaches including large scale human biosampling, pulmonary disease phenotyping, analytical mass spectrometry-based metabolomics and statistical epidemiology.

Dr. Alotaibi completed fellowship training in pulmonary and critical care at UC San Diego School of Medicine where she also completed an advanced fellowship in pulmonary vascular disease. She completed residency training at Case Western Reserve University in Cleveland, Ohio and earned her medical degree from King Abdulaziz University in Saudi Arabia. Dr. Alotaibi is board certified in internal medicine, pulmonary disease and critical care medicine.

She is a member of several professional societies including the American Thoracic Society, the American Heart Association and the Pulmonary Vascular Research Institute.

In her free time, Dr. Alotaibi enjoys cooking, reading, hiking and travel.



**Shaya A. Alshaya, MD**

Consultant Adult Pulmonary, Pulmonary Hypertension  
Head, Adult Pulmonary department at King Fahad Medical City  
Head, Pulmonary Hypertension Clinical Program & Service at King Fahad Medical City  
Program Director, Internal Medicine Residency Program, Riyadh Second Health Cluster  
*Riyadh, Saudi Arabia*

Dr. Shaya Ahmed Alshaya is currently a consultant pulmonologist and pulmonary hypertension specialist at King Fahad Medical City (KFMC), Riyadh, Saudi Arabia. He is the chairperson of the pulmonary hypertension clinical program at the same institute. He is the program director of Riyadh second health cluster, the internal Medicine residency program. He is the program director of Riyadh second health cluster Adult Pulmonary Fellowship program as well, both following Saudi counsel for health Specialists (SCFHS), Riyadh, Saudi Arabia. He received his MBBS from King Saud University, Riyadh, Saudi Arabia. He completed his training in the Internal medicine residency program and Adult Pulmonary Fellowship at KFMC, Riyadh, Saudi Arabia. He completed the clinical fellowship in Pulmonary Hypertension at the University of British Columbia, Vancouver, Canada.



**Bader J. Alghamdi, MD**

Consultant, Pulmonary Medicine, Pulmonary Hypertension, & Clinical Cardiopulmonary Exercise Testing  
Assistant Professor in King Saud bin Abdulaziz Uni. for Health Sciences (KSAU-HS)  
Section Head of Respiriology and Director of Respiriology Fellowship Training Program, Ministry of National Guard  
*Jeddah, Saudi Arabia*

Dr. Alghamdi attended medical school at King Abdulaziz University in Jeddah. Following this, he completed his residency training in Internal Medicine at King Abdulaziz Medical City (KAMC)-Jeddah. Then, he completed his fellowship in pulmonary medicine, pulmonary hypertension and advanced clinical cardiopulmonary exercise testing at Queen's University Kingston-Ontario-Canada. Currently, Dr. Alghamdi is a consultant in pulmonary medicine and pulmonary hypertension at KAMC.

He is the section Head of respirology and Chairman of joint training program of respirology fellowship in Western Region. He is an Assistant Professor in Internal medicine and pulmonary in King Saud bin Abdulaziz for Health Science (KSAU-HS) Jeddah. He has many publications in a well-respected journals with special interest in pulmonary hypertension and airway diseases.



**Hani Sabbour, MD, FACC, FHRS, FASE**

Consultant Cardiologist and Cardiac Electrophysiology  
Mediclinic  
*Abu Dhabi, UAE*

Dr. Hani Sabbour graduated with a Bachelor's Degree in Basic Medical Sciences and Bachelor's Degree in Medicine and Surgery from Kuwait University Faculty of Medicine in 1994 with first class honors and was twice awarded His Highness the Emirs Gold Medal for academic excellence in both degrees. He subsequently went on to train in Internal Medicine and Cardiovascular Disease at SUNY Stony Brook in New York and was elected resident and fellow of the year several times.

He then completed his training in Clinical Cardiac Electrophysiology at Massachusetts General Hospital and was appointed Clinical Instructor in Cardiology at Harvard Medical School in 2001 as well as SUNY Stony Brook.

He is currently American Board of Internal Medicine Certified in Internal Medicine, Cardiology, Electrophysiology, and Board Certified in Echocardiography and Nuclear Cardiology. He has always been heavily involved in teaching and been on the teaching faculty at Brown University since 2006.

He was recently promoted to Clinical Assistant Professor of Medicine and Cardiology at Brown University Warren Alpert School of Medicine. Dr. Sabbour has been active in research and is currently an active PI in two International multicenter trials in the field of pacing and ICDs and has had several publications in the field.

He was also appointed the Internal medicine residency program director at Al Ain Hospital as well as Arab Board Cardiology fellowship site director. He has been in practice in Rhode Island for 11 years and recently moved to the UAE to be on staff as Consultant Cardiologist at SKMC, Al Ain Hospital, and Tawam Hospitals. His main clinical interests are the management of Arrhythmias and Advanced CHF and Pulmonary HTN as well as cardiac imaging.



**Hussam M. Sakkijha, MD**

Consultant, Pulmonary,  
Critical Care and Sleep Medicine, King Fahad Medical City  
*Riyadh, Saudi Arabia*

Dr. Sakkijha is a consultant pulmonologist, intensivist and a sleep physician at King Fahad Medical City in Riyadh, Saudi Arabia. He is the Chairman of the Institutional Review Board at King Fahad Medical City. He is the co-chair of CTEPH taskforce in the SAPH and contributed extensively to the PH services in the region. He has many publications in the field and a Co-author of the Saudi Guidelines of the management of PH. He is an active member of Saudi Association of Pulmonary Hypertension and have been attending all the past conferences.



**Hassan M. Alnuaimat, MD**

Consultant Staff Physician, Pulmonary and Critical Care Medicine  
Director of the Pulmonary Hypertension,  
Program Cleveland Clinic  
*Abu Dhabi, UAE*

Dr. Hassan Alnuaimat is a Consultant Staff Physician who is specialized in Pulmonary and Critical Care Medicine. He is the Director of the Pulmonary Hypertension Program at Cleveland Clinic Abu Dhabi. Prior to joining Cleveland Clinic Abu Dhabi, Dr. Alnuaimat was a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Florida in Gainesville, Florida, USA.

Dr. Alnuaimat has advanced specialization in Pulmonary Hypertension, Lung Transplantation and ECMO support. He was the founder and Director of the PH comprehensive care center at the University of Florida. He was a leader in the 5th highest volume lung transplant program in the United States.

Dr. Alnuaimat was the Director of the Respiratory ECMO Program.

Dr. Alnuaimat is a well accomplished researcher. He has authored numerous research articles in leading peer-reviewed journals. Dr. Alnuaimat has lectured at, and his research work was presented in, numerous scientific meetings. He is an excellent clinical educator and has received numerous teaching awards





**Prof. Yoshihiro Fukumoto, MD, PhD, FJCC, FESC, FAHA, FJCS**

President, Japanese Pulmonary Circulation and Pulmonary Hypertension Society  
Deputy Director of Kurume University Hospital  
Professor and Chairman, Division of Cardiovascular Medicine, Department of Internal Medicine  
Kurume University School of Medicine  
*Kurume, Japan*

Yoshihiro Fukumoto is Professor and Chairman of Cardiovascular Medicine in the Department of Internal Medicine, Kurume University School of Medicine, and deputy director of Kurume University Hospital, who is also a Fellow of JCC, JCS, AHA, and ESC. Dr. Fukumoto was awarded his medical degree from Kyushu University School of Medicine and followed this with a PhD in coronary arteriosclerosis in Kyushu University, Fukuoka, Japan. After completing his residency, he spent time as a research fellow, clinical fellow, and clinician, working in both Japan and Brigham and Women's Hospital, Boston, MA, USA, before taking up the post of Associate Professor in the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan in 2011. Since July 2013, he has held the position of Professor and Chairman of Cardiovascular Medicine in the Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.



**Ali O. Abualsaud, MBBS, FRCPC**

Associate Professor of Medicine,  
McGill University, *Montreal, Canada*  
Consultant Interventional/Structural Cardiology and Adult Congenital Heart Disease  
King Fahad University Hospital, Imam Abdulrahman Bin Faisal University  
*AlKhobar, Saudi Arabia*

Dr. Abualsaud is an interventional cardiologist specializing in pulmonary vascular and structural heart disease. He completed internal medicine and adult cardiology training at McGill University, followed by fellowships in interventional cardiology at the Montreal Heart Institute and in Adult Congenital Heart Disease at McGill University.

At McGill, he served as Associate Professor of Medicine and established the Quebec provincial Balloon Pulmonary Angioplasty (BPA) program for chronic thromboembolic pulmonary hypertension performing nearly 250 BPA procedures after advanced training in Okayama, Japan. He also co-led one of Canada's leading Pulmonary Embolism Response Team (PERT) programs and served as Co-Director of a high-volume Transcatheter Aortic Valve Implantation (TAVI) program.

After 18 years abroad, he returned to Saudi Arabia to establish a BPA program at King Fahad University Hospital in Khobar, with a continued focus on advancing care for patients with pulmonary hypertension and adult congenital heart disease.



**Roberto Badagliacca, MD, PhD**

Professor, Department of Cardiovascular and Respiratory Science  
School of Medicine, University of Rome "Sapienza"  
*Rome, Italy*

Dr. Roberto Badagliacca is an internationally recognized cardiologist and academic leader in the field of pulmonary arterial hypertension (PAH). He serves as Associate Professor of Cardiology at Sapienza University of Rome, where his clinical, research, and teaching activities focus on advanced pulmonary vascular disease and right heart failure.

His academic training includes advanced clinical and research specialization in cardiovascular disease, cardiovascular imaging, and advanced heart failure. Dr. Badagliacca's scientific work centers on the pathophysiology of pulmonary arterial hypertension, imaging phenotyping, and risk stratification, contributing to improved diagnostic precision and patient-centered therapeutic strategies.

He is the Chairman Elect of the ESC Working Group on Pulmonary Circulation and Right Ventricular Function and has authored numerous peer-reviewed publications in high-impact international journals.



**Lama A. Alabdi, PhD**

Head Section, Developmental Genetics  
Department of Translational Genomics  
King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*

Dr. Lama Alabdi received PhD training in Dr. Humaira Gowher's laboratory at the Department of Biochemistry, Purdue University. Their doctoral research focused on the use of embryonic stem cells and embryonal carcinoma cell differentiation as model systems to mechanistically investigate the failure of enhancer silencing in cancer stem cells.

Following completion of the PhD, Dr. Lama Alabdi joined King Saud University, College of Science, as an Assistant Professor, while maintaining a long-standing collaboration with Prof. Fowzan S. Alkuraya as a scientist in his laboratory at King Faisal Specialist Hospital and Research Centre (KFSHRC), Department of Translational Genomics. Under Prof. Alkuraya's leadership, this work led to impactful discoveries and the publication of multiple high-impact research articles.

After transitioning from a traditional academic environment to a clinical research setting, Dr. Lama Alabdi joined the Center of Genomics Medicine at KFSHRC and was appointed Section Head of the Developmental Genetics Group within the Department of Translational Genomics.



**Ahmed Krimly, MD**

Consultant, Adult Congenital  
Heart Disease and Interventional Cardiology,  
King Faisal Cardiac Centre,  
King Abdul Aziz Medical City  
*Jeddah, Saudi Arabia*

Dr. Ahmed Krimly is a Consultant Interventional Cardiologist at King Faisal Cardiac Centre at the King Saud Bin Abdulaziz Medical City, Jeddah, Saudi Arabia. He is specialized in Adult, Adult congenital heart disease, Interventional and Obstetric cardiologist. Dr. Krimly was a consultant of Adult, Congenital Heart Disease and Interventional Cardiology in Jeddah, Saudi Arabia since 2013. He is also the Adjunct Assistant Professor of Internal Medicine and Cardiology King Saud bin Abdul Aziz University for Health Sciences in Jeddah, KSA.



**Ragdah H. Arif, MD, FRCPC, ABIM**

Consultant, Pulmonologist and Pulmonary Hypertension  
Assistant Professor, King Abdulaziz University/Hospital  
*Jeddah, Saudi Arabia*

Dr. Ragdah Arif is an Internal Medicine and Pulmonary Medicine Consultant, she is also currently the Pulmonary Hypertension Consultant and Assistant Professor at King Abdulaziz University, Jeddah, Saudi Arabia. She is a certified American board of internal medicine (ABIM), fellow of the Royal College of the Physicians of Canada (FRCPC) in Internal Medicine and Pulmonary Medicine.

Her recent publication in European Respiratory Journal open access 2021 (The treatment of Pulmonary Hypertension associated with Chronic Obstruction Airway Disease). Dr. Ragdah has presented herself as speaker and chair at several local and International Conferences including Saudi Thoracic Society in Riyadh 2021 And Pulmonary Hypertension Master Class 2021.



**Saleh A. Aldammas, MD**

Consultant, Pulmonary and Sleep Medicine  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*

Dr. Saleh Aldammas is currently a Senior Consultant of Internal Medicine at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. He is specialised in Pulmonary and Sleep Medicine. Also, he is working as an Associate Professor at Alfaisal Medical School. Dr. Aldammas is an active member of Saudi Association of Pulmonary Hypertension and have attended all past conferences.





**Prof. Chih-Hsin Hsu, MD, PhD**

President, Taiwan Society of Critical Care Medicine  
Professor of Medicine, College of Medicine, National Cheng Kung University  
Deputy Superintendent, National Cheng Kung University Hospital  
Director, Heart Failure and Pulmonary Hypertension Program,  
National Cheng Kung University Hospital  
*Tainan, Taiwan*

- PhD, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan
- Master Degree, Pulmonary Vascular Disease, University of Bologna, Italy
- Medical Doctor, China Medical College, Taichung, Taiwan
- Cardiovascular Disease, Heart Failure and Heart Transplantation, Pulmonary Hypertension, Critical Care Medicine, Myocardial Biopsy, Geriatrics
- Deputy Superintendent, National Cheng Kung University Hospital, Tainan, Taiwan
- Attending Physician, Department of Internal Medicine National Cheng Kung University Medical Center, Tainan, Taiwan
- Professor, National Cheng Kung University, Tainan, Taiwan
- Director, Heart Failure & Pulmonary Hypertension Program, National Cheng Kung University Hospital, Tainan, Taiwan



**Badr Alzahrani, MD, FACC**

Consultant Interventional Cardiology  
American Board of Internal medicine, Cardiology and Interventional Cardiology,  
Prince Sultan Cardiac Center  
*Riyadh, Saudi Arabia*

Dr. Badr Alzahrani is a Consultant Interventional Cardiology at the Prince Sultan Cardiac Center, Riyadh, Saudi Arabia. He is certified for American Board of Internal medicine and specialized in both Cardiology and Interventional Cardiology. He has attended several conferences.



**Khaled M. Alobaidellah, MD, FRCPC**

Consultant Adult Pulmonary,  
Pulmonary Hypertension,  
Pulmonary Medicine Division,  
Prince Sultan Military Medical City  
*Riyadh, Saudi Arabia*


Dr. Khaled Alobaidellah is currently an Internal Medicine and Pulmonary Medicine consultant at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. He received his Medical Degree from King Saud University. Following this he completed postgraduate training both in internal medicine and pulmonary medicine in Riyadh and holds the Saudi Board of Internal Medicine, and Fellowship in Pulmonary Medicine. He also completed Clinical Fellowship in Pulmonary Hypertension at the University of British Columbia in Vancouver, Canada. He has attended several conferences.



**Noura Alturaif, MD**

Consultant, Pulmonary and Pulmonary Hypertension  
Lung Health Department, King Faisal Specialist Hospital & Research Centre  
*Riyadh, Saudi Arabia*

Dr. Noura Alturaif embarked on her medical journey at King Saud University in Riyadh. Following her educational foundation, she pursued a residency at KFSH&RC, which laid the groundwork for her extensive training in Internal Medicine, Pulmonary, and Critical Care at the University of Virginia, USA. Dr. Alturaif's commitment to patient care led her to specialize in Pulmonary Vascular Disease during a dedicated year at Stanford University. Her research is focused on evaluating the outcomes of patients with pulmonary arterial hypertension (PAH). Presently, she serves as an active Pulmonary and Pulmonary Hypertension Consultant at KFSH&RC in Riyadh.







provided greater clinical improvement than continuing treatment with a PDE5i<sup>1</sup>

- References:**
1. Hoepfer MM, Al-Hiti H, Benza RL, et al. Switching from phosphodiesterase type 5 inhibitors to riociguat in patients with pulmonary arterial hypertension: The REPLACE study. Poster presented at: ERS 2020 International Conference Virtual Platform; September 7-9, 2020.
  2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (European Heart Journal; 2022 – doi: 10.1093/eurheartj/ehac237 and European Respiratory Journal; 2022 – doi: 10.1183/13993003.00879-2022)

Manufacturer & Marketing Authorisation holder: Bayer AG 51368 Leverkusen, Germany

**For further details, please contact:**



**Bayer Middle East FZE**  
Dubai Science Park – North Tower (13th. Floor)  
P.O. Box: 500829  
Dubai, United Arab Emirates  
Phone: +971 4 4452700

**Web:** <https://www.bayer.com/ar/ae/middle-east-ar-home>

**\*\* For Safety Reporting: [www.safetrack-public.bayer.com](http://www.safetrack-public.bayer.com) or [pv.me@bayer.com](mailto:pv.me@bayer.com)**

\*\*\* Information sent to the above contact details is subject to Bayer Privacy Statement for Pharmacovigilance Data (<https://www.bayer.com/en/privacy>)

Bayer Privacy Statement for Pharmacovigilance Data (<https://www.bayer.com/en/privacy-statement-pv>) and might be transferred outside your country, including but not limited to, transfer outside the United Arab Emirates.

ME PIL version: Nov., 2021

***Needs.  
Science.  
Trust.***

**WWW.AOP-HEALTH.COM**

PP-ADE-BH-0039-1



**PIONEERING.  
LEADING.  
ENGAGING.**



***Treat PAH differently by  
adding a first-in-class activin  
signalling inhibitor (ASI)<sup>1</sup>***

**SAY YES TO MORE**



Expanding Access To Healthcare For  
Innovative Medical Solutions In The Mena Region.



Scan for Selected Safety Information


**References:**

1.Hoeper MM et al. N Engl J Med. 2023;388:1478–1490.

Copyright © 2026 Merck Sharp & Dohme Corp., MSD Saudi Arabia is a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.  
SA-SOT-00035. Expiry Date: 06/01/2028

To report an adverse event, product quality complaint and other reportable information or if you have a medical inquiry, you can contact: Tel: +966112506700 Fax: +966 11 2506870  
Email: DPOC.SAUDI@MSD.COM  
MSD Building #3, Business Gate, Airport Road, Qurtubah, Riyadh 13244 PO Box 17098 Saudi Arabia

**GET CONNECTED**



[www.biologixpharma.com](http://www.biologixpharma.com)  
Dubai Airport Free Zone, UAE  
[info@biologixpharma.com](mailto:info@biologixpharma.com)



**Maacy**<sup>®</sup>  
Macitentan 10mg  
film coated tablet

IS NOW  
  
SAUDI  
MADE

*Break the chain  
Empower the Journey*



**BOSENTOR**<sup>®</sup>  
Bosentan Monohydrate Tablets




Available in:

62.5 mg Tablet

125 mg Tablet



Helping you bring patients back to  
health through the same quality  
medicine dispensed in Canada



  
**PPI**  
Promise & Commitment



# Smart. Innovation.

The monitoring platform of the future.



SVR  
MAP  
HPI  
CO

HemoSphere advanced monitoring platform



Edwards

## SPONSORS



Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.



An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.

A growing and aging world population requires an adequate supply of food and improved medical care.

With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development

activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

Our goal is to create value for our customers, stockholders and employees, while also strengthening the company's earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer. All this goes to make up our purpose.



## SPONSORS



AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates

worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company's actions.



MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world and today, we are at the forefront of research to

deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

For more information, visit [www.msd.com](http://www.msd.com) and connect with us on Facebook, LinkedIn, Youtube, Instagram and X (Twitter) at MSD GCC.



Sudair Pharmaceutical Company (SPC) is a limited liability Saudi company, established in 2014 in order to build an "Advanced Pharmaceutical Industrial Complex" to fulfill the unmet in the pharmaceutical market with a Vision to improve lives through localizing advanced therapies by increasing the accessibility of high-quality medicinal products, building a professional team to localize and develop a cutting edge manufacturing technologies.

In Sudair Pharma we started our operation in the KSA market through building the 1st manufacturing facility in the region dedicated for anti-neoplastic agents (oral & IV) then we expanded our portfolio through building a dedicated site for specialized products that cover different therapy areas like Multiple Sclerosis, Neurology, Anti-coagulation & Pulmonary Hypertension.

## SPONSORS



Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the MENA region. Positioned across 17+ key strategic locations in the GCC, Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases. A privately owned pharmaceutical company organized under the laws of UAE, Biologix provides end-to-end solutions from

the preregistration phase all the way to commercial-scale market access and risk management including:

- Named patient supply
- Pharmaceutical registration
- Awareness and promotional campaigns
- Cold chain distribution
- Tender and risk management
- Pharmacovigilance and product safety

Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches. Biologix main partners include: Advanz Pharma, ALK, BMS, Chiesi, Amgen, Incyte, Takeda, Marinus...

Biologix premises are being regularly audited by the UAE Ministry of Health & Prevention and by its Principals and business partners. Furthermore, the company has acquired the ISO 9001:2015 Certification.



Founded in 1983, Pharmascience inc. is the largest pharmaceutical employer in Québec, Canada, with over 1500 employees proudly headquartered in Montréal and global presence in over 60 countries. Our presence in the Middle East region expanded in the past 5 years with the sole purpose of providing patients across the region with access to affordable highest standard Canadian quality medications. Pharmascience is ranked among Canada's top R&D

investors. Pharmascience is a leading manufacturer and marketer of prescription and OTC medications as well as FDA-approved Canadian made injectables. The company commercializes more than 300 product families in 20 different dosage forms for over 2000 products. In Canada alone, more than 45 million prescriptions are filled annually with Pharmascience products. In 2018 Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers. We have a strong long-standing philanthropic ties with our communities, For more than 20 years, Pharmascience has been working through Health Partners International of Canada (HPIC) as a partner of choice to increase access to medicine with donations surpassing \$70 million.



## SPONSORS



Qomel is a healthcare provider company specializing in specific treatment areas: offering healthcare professionals high-quality products and services.

Among those areas is Pulmonary Hypertension which we partnered with OHRE PHARMA (France) to supply top-quality European medicines: including Sildenafil 20 mg for (Pulmonary Hypertension) and Bosentan 125 mg & 62.5.



BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and more than 70,000 employees have a passion and commitment to

help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

<https://www.bd.com/en-us/about-bd/our-company?activetab=1#aboutbd>

# SAPH 2027

**14-16 JANUARY | RIYADH, KSA**

**THE 20<sup>TH</sup> ANNUAL CONFERENCE OF  
THE SAUDI ASSOCIATION FOR PULMONARY HYPERTENSION**

# MARK YOUR CALENDAR



## CONTACT:



Email: [saphsts@gmail.com](mailto:saphsts@gmail.com)

© Saudi Association for Pulmonary Hypertension/ Saudi Thoracic Society, All Rights Reserved.